PMID- 1710768
OWN - NLM
STAT- MEDLINE
DCOM- 19910717
LR  - 20210526
IS  - 0270-7306 (Print)
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Linking)
VI  - 11
IP  - 7
DP  - 1991 Jul
TI  - Identification of cis sequences controlling efficient position-independent 
      tissue-specific expression of human major histocompatibility complex class I 
      genes in transgenic mice.
PG  - 3564-72
AB  - We previously reported that genomic major histocompatibility complex class I 
      human leukocyte antigen (HLA)-B7 gene constructs with as little as 0.66 kb of 5'- 
      and 2.0 kb of 3'-flanking DNA were expressed efficiently and appropriately in 
      transgenic mice. To identify and characterize the relevant cis-acting regulatory 
      elements in more detail, we have generated and analyzed a series of transgenic 
      mice carrying native HLA-B7 genes with further 5' truncations or intronic 
      deletions and hybrid constructs linking the 5'-flanking region of B7 to a 
      reporter gene. We were unable to detect a specific requirement for sequence 
      information within introns 2 to 7 for either appropriate constitutive or 
      inducible class I expression in adult animals. The results revealed the presence 
      of cis-acting regulatory sequences between -0.075 kb and -0.66 kb involved in 
      driving efficient copy number-dependent constitutive and gamma 
      interferon-enhanced tissue-specific expression. The region from -0.11 to -0.66 kb 
      is also sufficient to prevent integration site-specific "position effects," 
      because in its absence HLA-B7 expression is frequently detected at significant 
      levels at inappropriate sites. Conserved sequence elements homologous to the H-2 
      class I regulatory element, or enhancer A, and the interferon response sequence 
      are located between about -151 and -228 bp of the B7 gene. Our results also 
      indicate the existence of sequences downstream of -0.11 kb which can influence 
      the pattern of tissue-specific expression of the HLA-B7 gene and the ability of 
      this gene to respond to gamma interferon.
FAU - Chamberlain, J W
AU  - Chamberlain JW
AD  - Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Vasavada, H A
AU  - Vasavada HA
FAU - Ganguly, S
AU  - Ganguly S
FAU - Weissman, S M
AU  - Weissman SM
LA  - eng
GR  - CA42556/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
RN  - 0 (HLA-B7 Antigen)
RN  - 0 (Recombinant Proteins)
RN  - 63231-63-0 (RNA)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - DNA/genetics/isolation & purification
MH  - Gene Expression
MH  - *Gene Expression Regulation/drug effects
MH  - *Genes, MHC Class I
MH  - *Genes, Regulator
MH  - HLA-B7 Antigen/*genetics
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - Mice
MH  - Mice, Transgenic
MH  - Nucleic Acid Hybridization
MH  - RNA/genetics/isolation & purification
MH  - Recombinant Proteins
MH  - Transcription, Genetic/drug effects
PMC - PMC361100
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
PMCR- 1991/07/01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PHST- 1991/07/01 00:00 [pmc-release]
AID - 10.1128/mcb.11.7.3564-3572.1991 [doi]
PST - ppublish
SO  - Mol Cell Biol. 1991 Jul;11(7):3564-72. doi: 10.1128/mcb.11.7.3564-3572.1991.